Aileron Therapeutics, Inc. (ALRN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

195.05 k

Shareholding (Mar 2025)

FII

0.35%

Held by 5 FIIs

DII

83.32%

Held by 5 DIIs

Promoter

11.74%

How big is Aileron Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Aileron Therapeutics, Inc. has a market capitalization of 39.88 million and reported net sales of 0.00 million with a net profit of -61.27 million over the last four quarters. The balance sheet shows shareholder's funds of 54.39 million and total assets of 69.24 million.

What does Aileron Therapeutics, Inc. do?

22-Jun-2025

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing stapled peptides for cancer, endocrine and metabolic diseases, and inflammation. It has a market cap of approximately $39.88 million and reported a net profit loss of $6 million as of March 2025.

Who are in the management team of Aileron Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Aileron Therapeutics, Inc. includes Chairman Jeffrey Bailey, CEO Dr. Manuel Aivado, Lead Independent Director Dr. Reinhard Ambros, and Independent Directors William McKee, Jodie Morrison, Nolan Sigal, and Josef von Rickenbach. They oversee the company's strategic direction and operations.

Is Aileron Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Aileron Therapeutics, Inc. shows a mildly bearish trend with mixed signals from indicators, significantly underperforming the S&P 500 with a year-to-date return of -50.0%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 31 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.12

Return on Equity

-46.14%

Price to Book

0.65

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

10.32%

6 Months

-31.19%

1 Year

-46.54%

2 Years

-43.72%

3 Years

-50.53%

4 Years

-88.02%

5 Years

-93.32%

Aileron Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Aileron Therapeutics, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Aileron Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and both the weekly and monthly Bollinger Bands and KST are bearish, suggesting ongoing downward pressure. The Dow Theory shows no trend on the weekly timeframe and is mildly bearish on the monthly timeframe. In terms of performance, Aileron has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -50.0% compared to the S&P 500's 12.22%, and a one-year return of -56.6% versus 17.14%. Overall, the current technical stance is mildly bearish, with mixed signals from various indicators....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

1.60%

EBIT to Interest (avg)

-24.47

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.15

Sales to Capital Employed (avg)

Tax Ratio

2.46%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

37.28%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.89

EV to EBIT

-1.39

EV to EBITDA

-1.39

EV to Capital Employed

0.87

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-62.46%

ROE (Latest)

-48.66%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (4.6%)

Foreign Institutions

Held by 5 Foreign Institutions (0.35%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 23.60% vs -394.44% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.90",
          "val2": "-9.00",
          "chgp": "23.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.80",
          "val2": "-8.90",
          "chgp": "23.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -300.64% vs 42.49% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.00",
          "val2": "-15.20",
          "chgp": "-84.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-37.00",
          "val2": "-0.90",
          "chgp": "-4,011.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.90",
          "val2": "-15.70",
          "chgp": "-300.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.90

-9.00

23.33%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-6.80

-8.90

23.60%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 23.60% vs -394.44% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-28.00

-15.20

-84.21%

Interest

0.00

Exceptional Items

-37.00

-0.90

-4,011.11%

Consolidate Net Profit

-62.90

-15.70

-300.64%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -300.64% vs 42.49% in Dec 2023

All Annual Results

Company CV

About Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

Company Coordinates

Company Details

290 PLEASANT STREET, UNIT 112 , WATERTOWN MA : 02472

Tel: 1 617 9950900

http://www.aileronrx.com/

Registrar Details

Aileron Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Aileron Therapeutics, Inc.?

Watch in Real-Time

What does Aileron Therapeutics, Inc. do?

Who are in the management team of Aileron Therapeutics, Inc.?

Is Aileron Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Aileron Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Aileron Therapeutics, Inc.

Company Coordinates